Revolution Medicines, Inc.
RVMD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $12 | $35 | $29 |
| % Growth | -100% | -67.3% | 20.4% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $12 | $35 | $29 |
| % Margin | – | 100% | 100% | 100% |
| R&D Expenses | $592 | $423 | $253 | $187 |
| G&A Expenses | $97 | $76 | $41 | $30 |
| SG&A Expenses | $97 | $76 | $41 | $30 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $690 | $499 | $294 | $217 |
| Operating Income | -$690 | -$487 | -$258 | -$188 |
| % Margin | – | -4,207.1% | -730% | -639.7% |
| Other Income/Exp. Net | $89 | $47 | $9 | $1 |
| Pre-Tax Income | -$601 | -$440 | -$249 | -$187 |
| Tax Expense | -$1 | -$4 | -$0 | $0 |
| Net Income | -$600 | -$436 | -$249 | -$187 |
| % Margin | – | -3,768.3% | -703% | -636.6% |
| EPS | -3.58 | -3.86 | -3.08 | -2.47 |
| % Growth | 7.3% | -25.3% | -24.7% | – |
| EPS Diluted | -3.58 | -3.86 | -3.08 | -2.47 |
| Weighted Avg Shares Out | 168 | 113 | 81 | 73 |
| Weighted Avg Shares Out Dil | 168 | 113 | 81 | 73 |
| Supplemental Information | – | – | – | – |
| Interest Income | $87 | $47 | $9 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $12 | $9 | $10 | $7 |
| EBITDA | -$678 | -$478 | -$249 | -$180 |
| % Margin | – | -4,126.7% | -702.7% | -611.6% |